Clinical trial · Observational
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
NCT05059951CI-TRIAL-00077690CREATErecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immune checkpoint inhibitor | Drug | Immune Checkpoint Inhibitor | ALIAS |
Design
Arms and outcomes
Arms (12)
- label
- Cohort A
- description
- Extansive Stage Small Cell Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors .
- interventionNames
- Drug: Immune checkpoint inhibitor
- label
- Cohort B
- description
- Limit Stage Small Celll Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors .
- interventionNames
- Drug: Immune checkpoint inhibitor
- label
- Cohort C
- description
- Small Celll Lung Cancer who progressed from first line treatment and received subsequential Chemotherapy with or without Checkpoint Inhibitors.
- interventionNames
- Drug: Immune checkpoint inhibitor
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. ≥18，Lung Cancer Confirmed by Histopathology 2. Treated with Chemotherapy with or Without Checkpoint Inhibitors. 3. ECOG 0 - 1. 4. Predicted survival ≥ 12 weeks. 5. Adequate bone marrow hematopoiesis and organ function 6. Presence of measurable lesions according to RECIST 1.1. 7. Subjects with stable brain metastases may be included in the study. Exclusion Criteria: Patients did not match for the Inclusion Criteria.
References
Publications (0)
Data not yet available
No reference posted for this study.